Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 14/20 | 0.41 |
| ▸ | RXRG | P48443 | 12/20 | 0.41 |
| ▸ | RXRB | P28702 | 11/20 | 0.41 |
| ▸ | CYP26A1 | O43174 | 5/20 | 0.39 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.39 |
| ▸ | RARG | P13631 | 4/20 | 0.38 |
| ▸ | RARB | P10826 | 3/20 | 0.37 |
| ▸ | RARA | P10276 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6476670 | 1.00 | RXRA (0.41) | RXRARXRGRXRBCYP26A1CYP26B1 | |
| SCHEMBL7153988 | 0.89 | RXRA (0.42) | RXRARXRGRXRBCYP26A1CYP26B1 | |
| SCHEMBL6472228 | 0.85 | RXRA (0.47) | RXRARXRGRXRBCYP26A1CYP26B1 | |
| SCHEMBL6472234 | 0.85 | RXRA (0.47) | RXRARXRGRXRBCYP26A1CYP26B1 | |
| SCHEMBL6472410 | 0.84 | CYP26B1 (0.41) | RXRARXRGRXRBCYP26A1CYP26B1 | |
| SCHEMBL6472409 | 0.84 | CYP26B1 (0.41) | RXRARXRGRXRBCYP26A1CYP26B1 | |
| SCHEMBL7563931 | 0.77 | RXRA (0.39) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL7562932 | 0.77 | RXRA (0.40) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL6478019 | 0.77 | RXRA (0.39) | RXRARXRGRXRBRARGRARB | |
| SCHEMBL7562936 | 0.77 | RXRA (0.40) | RXRARXRGRXRBRARGRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6444709-B1 | SKIN DISORDERS; ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2002-09-03 | — | — | US | claimed |
| US-6921777-B2 | Heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-07-26 | — | — | US | disclosed |
| US-20030012803-A1 | Novel heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-01-16 | — | — | US | disclosed |
| US-6444709-B1 | SKIN DISORDERS; ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2002-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030012803-A1 | Novel heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them | TYR, CYP1B1, MITF | RXRA 935/4885RXRG 663/4885RXRB 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.